Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Friday, May 22, 2015 2:45:18 PM
View it in your browser.
My Fellow Cellceutix Shareholders,
Many investors are aware that when a company announces plans to uplist to a senior exchange, they attract and become vulnerable to those engaged in short selling. These people/funds take short positions trying to drive a stock down and hope for a reverse split to be necessary to meet share price requirements for the senior exchange. The companies are viewed as easy prey, as often these companies need to uplist in order to meet conditions of a financing.
We’re not splitting our stock. We have cash on hand and an equity line. Long term shareholders know we’ve been through these short attacks before and each time the stock recovered and reached new highs. As far as the uplist, it is in progress with NASDAQ.
If one has doubt as to the potential of our lead anti-cancer drug Kevetrin, I encourage you to read this morning’s press release disclosing that the Institutional Review Board (IRB) approved additional enrollment for our trial of Kevetrin for solid tumors at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Typically, we are not inclined to release news on Fridays, but we wanted to share this – what we consider to be fantastic – news immediately with our shareholders.
Understand that Harvard Cancer Centers sit among the elite in the country for cancer research. The Scientific Review Committee and IRB had no obligation to allow for additional enrollment in our trial. After treating forty patients, would they want to treat more patients with a drug candidate that they don’t believe has potential? Of course not. We interpret the IRB approval as a strong vote of confidence as to the safety and potential impact of Kevetrin.
Thank you for your continued support.
Sincerely,
Leo Ehrlich, Chief Executive Officer, Cellceutix
Copyright © 2015 Cellceutix Corporation, All rights reserved.
You requested to receive email alerts about Cellceutix at our website www.cellceutix.com
Our mailing address is:
Cellceutix Corporation
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Add us to your address book
Email Marketing Powered by MailChimp
unsubscribe from this list | update subscription preferences
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM